Background CASSIOPEIA part 1 demonstrated superior depth of response and prolonged
progression-free survival with daratumumab in combination with bortezomib, thalidomide …

Background CASSIOPEIA part 1 showed superior depth of response and significantly
improved progression-free survival with daratumumab, bortezomib, thalidomide, and …

Background In part 1 of the two-part CASSIOPEIA study, treatment before and after
autologous haematopoietic stem-cell transplantation (HSCT) with daratumumab plus …

Background Bortezomib, thalidomide, and dexamethasone (VTd) plus autologous stem-cell
transplantation is standard treatment in Europe for transplant-eligible patients with newly …

Background In the primary analysis of the phase 3 MAIA trial (median follow-up 28· 0
months), a significant improvement in progression-free survival was observed with …

Background Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (D-
RVd) in the GRIFFIN study improved the stringent complete response rate by the end of …

The randomized, phase 2 GRIFFIN study (NCT02874742) evaluated daratumumab plus
lenalidomide/bortezomib/dexamethasone (D-RVd) in transplant-eligible newly diagnosed …

Background Standard-of-care treatment for patients with newly diagnosed multiple myeloma
includes combination therapies for patients who are not eligible for autologous stem-cell …

Introduction: Daratumumab (DARA) is approved across lines of therapy for multiple
myeloma. In the primary analysis of the randomized phase 2 GRIFFIN trial (NCT02874742) …

Background Daratumumab, lenalidomide and dexamethasone (DRd) and bortezomib,
lenalidomide and dexamethasone (VRd) are preferred regimens for transplant ineligible …